Two biotechs new to Nasdaq sparked more investor interest than originally expected Wednesday, hauling upsized IPOs that are yet another indication of the industry’s rip-roaring state.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,